Cancer Research UK, a company limited by guarantee and a registered charity, is governed by a Council of Trustees, the Charity’s board of directors.
Council’s role is to set the Charity’s strategic direction, monitor the delivery of the Charity’s objects, uphold its values and governance and guide, advise and support the Chief Executive, who leads the Senior Management Team towards achieving the Charity’s vision and purpose.
The Council of Trustees is led by the Chairman, Professor Sir Leszek Borysiewicz.
If you are interested in becoming a Trustee, please go to our jobs and careers website to read more about the role.
Professor Sir Leszek Borysiewicz MA PhD FRS FRCP FMedSci (Chairman)
Appointed 2016. Sir Leszek was appointed as a Trustee in July 2016 and as Chairman in November 2016. Following a distinguished academic and clinical research career and prior to his appointment as Vice-Chancellor of the University of Cambridge in 2010, Sir Leszek’s roles included Chief Executive of the Medical Research Council and Deputy Rector of Imperial College London. He was also a founding Fellow of the Academy of Medical Sciences. His work in vaccines included Europe’s first trial of a vaccine for human papillomavirus to treat cervical cancer, research conducted at the University of Cardiff and funded by Cancer Research UK. He was knighted in 2001 for his pioneering work in vaccines.
Wendy Becker BA MBA (Deputy Chairman)
Appointed 2011. Wendy is a non-executive Director of NHS England, Great Portland Estates and Oxford University Press. She also serves as a Trustee of the Prince’s Trust and the Design Museum. In addition, she is a member of the Global Advisory Council for the Said Business School, Oxford and of the Board of Visitors of the Dickey Centre at Dartmouth College. In her executive career, Wendy was CEO of Jack Wills Limited, Group Chief Marketing Officer at Vodafone, CEO of TalkTalk Residential and a long-serving partner at McKinsey & Company.
Carolyn Bradley MA (Cantab)
Appointed 2015. Carolyn has extensive marketing and commercial experience from her executive career with Tesco, where her roles included Group Brand Director, UK Marketing Director, and Chief Operating Officer for Tesco.com.
She is now a non-executive Director with Legal & General Group plc, Marston’s plc., Majid Al Futtaim Retail LLC and The Mentoring Foundation. In addition she is a member of the Advisory Board for the Cambridge Judge Business School and works as an independent advisor advising on business and marketing strategy. Carolyn graduated from Cambridge University before joining Tesco, where she led many innovations such as the Clubcard loyalty scheme, the ‘Every Little Helps’ service campaign and the grocery home delivery business. Carolyn has also been a Trustee for the DrinkAware Trust.
Catherine Brown LLB (Hons)
Appointed 2015. Catherine has broad experience in strategy and organisational change, having previously been Group Strategy Director of Lloyds Banking Group, Executive Director HR of the Bank of England, and Chief Operating Officer of Apax Partners. Catherine is now a non-executive board member of the Cabinet Office and holds board positions in private equity backed financial services and technology companies. She is Chairman of The Plastic Economy, a manufacturer of low cost prosthetic limbs from recycled plastic. She is a trustee of Blue Cross and also has charity projects across the Himalayan region. She spent her early career as a banker before joining McKinsey and subsequently ran her own management consultancy for five years before moving into private equity at Apax Partners.
Appointed 2016. Peter Chambré is Chairman of a number of life science and healthcare companies. He is Chairman of Cancer Research Technology Ltd, the commercialisation arm of Cancer Research UK; Immatics Biotechnologies, a company developing new cancer immunotherapy treatments; and OneMed Group, the leading distributor of medical supplies to hospitals and care homes in Northern Europe. He was Chief Executive Officer of Cambridge Antibody Technology plc from 2002 until its acquisition by AstraZeneca in July 2006.
Dr Adrian Crellin MA FRCR FRCP
Appointed 2012. Specialising in radiotherapy, Dr Crellin is a consultant Clinical Oncologist. He was recently Vice-President of the Royal College of Radiologists and Dean of the Faculty of Clinical Oncology and is currently Chair of the NHS England National Clinical Lead on Proton Beam Therapy. This is a new radiotherapy treatment which can target tumours more accurately while causing less damage to surrounding healthy tissue. He is Chair of the NHS England Proton Overseas Programme National Clinical Reference Panel, NIHR National Speciality Lead for Radiotherapy and Chair of the Radiotherapy Information Strategy Group.
Dr Crellin's research expertise includes clinical trials and new treatments for pancreatic and oesophageal cancer, both priorities for Cancer Research UK. He studied medicine at the University of Cambridge and completed his medical training at three London Hospitals: St Bartholomew's, The Middlesex and Mount Vernon. He is a former Clinical Director at the Institute of Oncology in Leeds.
Professor Alexander Eggermont MD PhD
Appointed 2016. Professor Eggermont is Director General of the Institut Gustave Roussy Cancer Center in Paris, one of Europe’s leading comprehensive cancer centres. He is Professor of Oncology at the Paris-Sud University and also Professor of Surgical Oncology and Endowed Professor of International Networking in Cancer Research at the Erasmus University Medical Centre, Rotterdam. He holds the Joseph Maisin Chair in Oncology at the Catholic University of Louvain and was conferred the honour of Chevalier of the Legion d’Honneur in January 2015.
Professor Eggermont obtained his PhD in tumour immunology at the Erasmus University, Rotterdam in 1987. His clinical specialties include immunotherapy, melanoma, sarcoma and regional therapy techniques as well as general drug development. His basic research experience is in tumour immunology, advanced in vivo imaging models and tumour pathophysiology. He is a Fellow of the Surgery Branch of the National Cancer Institute, USA.
Professor Eggermont is President of the European Academy of Cancer Sciences and President of Cancer Core Europe. He chairs the Adjuvant Therapy Committee European Organisation for the Research and Treatment of Cancer (EORTC) Melanoma Group and is a past President of ECCO and EORTC.
Professor Dame Amanda Fisher DBE FRS FMedSci
Appointed 2017. Professor Fisher is Director of the Medical Research Council London Institute of Medical Sciences (MRC LMS) and jointly runs the MRC LMS's Lymphocyte Development Group. She is also Head of the Institute of Clinical Sciences at Imperial College London’s Hammersmith Campus.
She obtained her PhD from the University of Birmingham, before studying retrovirus biology at the National Institutes of Health, USA. She returned to London in 1987 to establish an ICRF-funded laboratory, joined Professor Pierre Chambon’s Institute in Strasbourg for three years to study mouse genetics, before establishing a research team at the newly formed MRC Clinical Sciences Centre (now MRC LMS).
Professor Fisher was awarded the EMBO Gold medal in 2002 and she is a fellow of the Academy of Medical Sciences and of the Royal Society. She was made a Dame in the New Year’s Honours 2017, for ‘her advocacy for women in science, her commitment to the public understanding of science and her training and mentoring of researchers, as well as her scientific achievements’.
Professor Stephen T Holgate CBE FMedSci
Appointed 2014. Professor Holgate is Clinical Professor of Immunopharmacology at the Faculty of Medicine in Southampton. Over 35 years he has studied asthma and related illnesses using a range of scientific approaches including epidemiology, pathology and immunology, pharmacology, experimental medicine and genetics with a strong translational emphasis.
Professor Holgate advises the UK Government and EU on issues relating to Medical Research, Air Pollution and Chemical Hazards. He was Chair of the Research Excellence Framework 2014 Main Panel for Medicine, Health and Life Sciences and is currently Chair of the Board of the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) and the UK Government Hazardous Substance Advisory Committee.
He was appointed Commander of the Order of the British Empire (CBE) in the 2011 Queen’s New Year’s Honours.
Appointed 2014. David is a chartered accountant and a non-executive Director and Chairman of the Audit Committees of Drax Group plc and Deputy Chairman of the Governors of the University of the Arts London. He has held other non-executive directorships and was a Trustee of the British Museum from 2000 to 2009. He spent almost 30 years as a Partner at Ernst & Young, and served as the lead audit Partner for numerous FTSE 100 companies during his career at the firm, and was also a member of the firm’s governing council for 15 years. He was Deputy Chairman of the Financial Reporting Review Panel from 2008 to 2012 and has served on a number of national and international professional bodies relating to financial reporting and the accountancy profession.
Andrew Palmer FCA (Treasurer)
Appointed 2014. Andrew was formerly Group Finance Director of Legal & General plc where he had also held a number of financial and operational roles in the asset management, insurance and international businesses. He is a non-executive Director and Chair of the Audit Committee at both Direct Line Insurance Group plc and Royal London Group plc. He is also Chairman of Royal Asset Management. Andrew is a panel member of the Financial Reporting Review Panel of the Financial Reporting Council and is a Trustee and Chairman of the Royal School of Needlework. He is a Fellow of the Institute of Chartered Accountants in England and Wales.
Professor Sir Bruce Ponder FRCP FMedSci FRS
Appointed 2015. Bruce Ponder is Emeritus Professor of Oncology at Cambridge and a Senior Group Leader in the Cancer Research UK Cambridge Institute. He was formerly Li Ka Shing Professor of Oncology, Founding Director of the Cancer Research UK Cambridge Research Institute and of the Cambridge Cancer Centre, and co-Director of both the Hutchison/MRC Research Centre and of the Strangeways Research Laboratories for Genetic Epidemiology.
Bruce Ponder trained in internal medicine in London, and then did his PhD at ICRF (now the Francis Crick Institute). He trained in Medical Oncology at the Dana Farber Cancer Institute, Harvard University. His clinical and research career was in the genetics of susceptibility to cancer.
Over the past 20 years he has led the development of a new laboratory and clinical centre for cancer research in Cambridge. Milestones have been the establishment of the Strangeways Laboratories for Genetic Epidemiology in 1997, the Hutchison/MRC Research Centre in 2001, the CRUK Cambridge Institute in 2007, and the designation of Cambridge as a CRUK Major Cancer Centre in 2015. He was knighted in 2008 for ”services to medicine”.
Professor Sir Mike Richards CBE MD FRCP FRCR (Hon) FRCPath (Hon)
Appointed 2017. Sir Mike Richards was appointed the First Chief Inspector of Hospitals for England at the Care Quality Commission (CQC) in July 2013. He retired in July 2017. He was Director for Reducing Premature Mortality at NHS England (2013-14) and National Cancer Director at the Department of Health (1999-2013). Prior to these appointments he was a consultant and reader in Medical Oncology at Guy’s and St Thomas’ NHS Trust (1986-1995) and Professor of Palliative Medicine (1995-1999). He was appointed CBE in 2001 and Knight Batchelor in 2010 for services to medicine.
Get in touch
If you require further information or have any comments please get in touch.